Developer docs
API playgroundTry for free, no card

Search company profiles

EndoQuest Robotics

Full company profile

uuid0000bwy

Namestring
EndoQuest Robotics
Legal namestring
EndoQuest Robotics, Inc.
Company typeenum
Private
Founded yearint
2022
Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
51–100
akta.pro rankint
HeadquartersHouston, United States
HQ citystring
Houston
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices2 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
flexible robotic surgery, endoluminal surgical systems, surgical robotics platform, minimally invasive robotics, natural orifice surgery
Industry5 codes
PRIMARYHLAHADAF
Surgical Robotics & Computer-Assisted Surgery Platforms
Healthcare & Life Sciences/Medical Devices & Diagnostics/Surgical Instruments, Endoscopy & OR Equipment
SECONDARYHLAHADAB
Endoscopy Systems & Accessories (Scopes, Cameras, Light Sources, Insufflation)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Surgical Instruments, Endoscopy & OR Equipment
SECONDARYHLAHADAA
Open & Minimally Invasive Surgical Instruments (Handheld, Laparoscopic, MIS)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Surgical Instruments, Endoscopy & OR Equipment
SECONDARYHLAKAEAC
Advanced Endoscopy (ERCP/EUS/Interventional)
SECONDARYHDAAAIAC
Healthcare & Assistive Robotics
NAICS code3 codes
  • Surgical and Medical Instrument Manufacturing339112
  • Navigational, Measuring, Electromedical, and Control Instruments Manufacturing3345
  • Electromedical and Electrotherapeutic Apparatus Manufacturing334510
SIC code2 codes
  • Surgical & Medical Instruments & Apparatus3841
  • Electromedical & Electrotherapeutic Apparatus3845
Product category
Surgical Robotics
Social media profiles2 records
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model2 records
1Endoluminal Surgical System (Hardware + Software)
TypeHardware Sales
Description

Pre-revenue company. The Endoluminal Surgical System is currently in development and not yet FDA cleared or for commercial sale in the U.S. Revenue will be generated through hardware sales of the robotic surgical system along with associated software, instruments, and consumables to healthcare institutions.

mddionline.com
2Service and Support
TypeProfessional Services
Description

Expected to include installation, training, maintenance contracts, and technical support services for healthcare institution customers, typical for medical device capital equipment.

mddionline.com
Marketing channels5 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Technology or R&D, Personnel, Operations, Marketing or Sales, Others
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

EndoQuest Robotics develops the Endoluminal Surgical (ELS) System, a flexible robotic platform that enables minimally invasive surgery through the body's natural orifices (transoral, transanal, transvaginal) or single-incision (transumbilical) approaches. The integrated system comprises a mobile Patient Cart with the EndoDrive flexible steerable delivery system, 6mm flexible robotic instruments with up to 7 degrees of freedom, a 3.7mm HD robotic camera, and an ergonomic Physician Console with heads-up HD monitor and hand/foot controllers. The product is pre-commercial, currently in U.S. FDA IDE pivotal trials.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 value
  • First fully robotic endoscopic submucosal dissection (ESD) procedure by a gastroenterologist successfully removed a 4 cm colorectal lesion
Product overview1 text field

EndoQuest Robotics offers the Flexible Robotic Surgical System as its core product, a comprehensive platform designed to enable endoluminal and single-incision minimally invasive surgery through natural body orifices or minimal incisions. The system consists of three integrated components: the Patient Cart (featuring the EndoDrive and Removable Touchpad), the Flexible Instruments (with up to 7 degrees of freedom), and the Physician Console (with heads-up HD display and hand controllers). The platform is undergoing clinical development with the PARADIGM pivotal trial and is enhanced with AI-powered capabilities through NVIDIA IGX Thor integration for real-time image processing, tissue differentiation, and cloud intelligence. The company maintains worldwide headquarters in Houston, Texas and a South Korea office. The ELS System is under development and has not been FDA cleared for commercial sale in the United States.

Product and service1 record
1Endoluminal Surgical (ELS) System
CategorySurgical Robotics Platform
Description

A comprehensive flexible robotic surgical platform enabling endoluminal and single-incision procedures through the body's natural orifices (mouth, anus) or transumbilical incision. The integrated system includes a mobile Patient Cart with EndoDrive steerable delivery system, 6mm flexible instruments with up to 7 degrees of freedom, a 3.7mm HD robotic camera, and an ergonomic Physician Console. Designed for hospitals, ambulatory surgical centers, and gastroenterology/colorectal surgeons performing minimally invasive GI and general surgical procedures.

Scale indicator6 records

Each record includes

Type, Value, Description, Source

Partnership5 partners
Strategic tierCoreTypeTechnology or IntegrationAnnounced on2026-01-18
Description

EndoQuest expanded collaboration with NVIDIA to integrate AI-powered capabilities into its surgical robotic system. Leveraging NVIDIA's IGX Thor platform for real-time image processing, robotic control, cloud-enabled intelligence, intraoperative tissue differentiation, autonomous surgical tasks, and remote robotic operation capabilities.

Strategic tierCoreTypeTechnology or IntegrationAnnounced on2024-01-05
Description

Partnership to equip the flexible robotic system with industry-leading image sensor technology for enhanced visualization during surgical procedures.

Strategic tierMinorTypeStrategic or Co-development PartnerAnnounced on2023-03-16
Description

Multi-year partnership for surgical collaboration and documentation technology integration.

Strategic tierMinorTypeStrategic or Co-development PartnerAnnounced on2023-02-01
Description

Partnership to develop an endoluminal robotic training simulator for physician education and skill development.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2022-08-31
Description

Installation of the first Endoluminal Surgical System at Brigham and Women's Hospital in Boston, Massachusetts to advance clinical and procedural development of the ELS System.

Recent move7 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Moon Surgical builds a smaller, flexible robotic surgical assistance platform for laparoscopic procedures, aiming to broaden access to robotic surgery. Comparable in stage and ambition to EndoQuest: a smaller, well-funded surgical robotics entrant focused on novel flexible architectures.

TypeBroad incumbent
Description

Boston Scientific has significant GI/endoscopy franchises (including single-use endoscopes and ESD tools) and broader minimally invasive surgery businesses. It is a relevant incumbent and potential acquirer/competitor in the GI endoluminal procedure space.

TypeBroad incumbent
Description

Medtronic launched the Hugo robotic-assisted surgery system and has extensive GI/endoscopy businesses (including PillCam and GI solutions). As a broad incumbent, Medtronic competes in both EndoQuest's robotics and downstream GI endoscopy/endoluminal adjacencies.

TypeDirect peer
Description

Asensus Surgical develops the Senhance digital laparoscopic platform and is building a next-gen surgical robotics system with AI-enabled clinical intelligence. Both companies are pursuing digitally enhanced, next-generation minimally invasive surgical systems targeting GI and general surgery.

TypeBroad incumbent
Description

Intuitive Surgical is the dominant surgical robotics company with the da Vinci platform (including the da Vinci SP single-port system). It operates broadly across urology, gynecology, general surgery, and thoracic, with the largest installed base globally and an unmatched clinical evidence library — a clear incumbent benchmark EndoQuest must compete against.

TypeBroad incumbent
Description

Stryker offers the Mako robotic system for orthopedic surgery and acquired MAKO Surgical and Wright Medical, expanding its surgical robotics presence. While primarily orthopedic-focused, Stryker is a broad surgical robotics incumbent with growing interest in minimally invasive and AI-enabled surgery.

TypeDirect peer
Description

Vicarious Surgical develops single-incision surgical robotics with decoupled actuators for abdominal procedures. Both companies target minimally invasive surgery through small or single incisions using novel robotic architectures, with EndoQuest focused on flexible endoluminal and Vicarious on transabdominal single-port.

TypeBroad incumbent
Description

Olympus is the global leader in GI endoscopy systems and a natural incumbent in flexible endoluminal procedures. While primarily an endoscopy device manufacturer, Olympus has invested in robotic-assisted endoscopy and could expand into endoluminal robotics — directly adjacent to EndoQuest's primary use cases (ESD, myotomy, GI interventions).

TypeEmerging player
Description

Medrobotics developed the Flex Robotic System, a flexible robotic platform for natural orifice procedures (transoral, transanal) — directly comparable endoluminal technology. Although the company has faced restructuring, its technical approach and clinical use cases overlap materially with EndoQuest's platform.

TypeBroad incumbent
Description

Johnson & Johnson is developing the Ottava general surgery robotic platform and acquired Auris Health for Monarch bronchoscopy/endoluminal robotics. As a broad incumbent with substantial R&D resources, J&J represents the most credible threat to extending into flexible endoluminal surgery.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks7 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers2 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile1 record

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

Integration2 records

Each record includes

Title, Type, Description, Source

AI capability5 records

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature6 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles6 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
Compliance1 record

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds5 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors5 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

EndoQuest Robotics

Surgical Roboticsendoquestrobotics.com

EndoQuest Robotics firmographics

Firmographics
Name
EndoQuest Robotics
Legal name
EndoQuest Robotics, Inc.
Website
https://endoquestrobotics.com
Company type
Private
Founded year
2022
Operating status
Operating
Headcount range
51–100 employees
Ownership category
akta.pro rank

EndoQuest Robotics industry classification

Industry
Product category
Surgical Robotics
NAICS
Surgical and Medical Instrument Manufacturing (339112), Navigational, Measuring, Electromedical, and Control Instruments Manufacturing (3345), Electromedical and Electrotherapeutic Apparatus Manufacturing (334510)
SIC
Surgical & Medical Instruments & Apparatus (3841), Electromedical & Electrotherapeutic Apparatus (3845)
akta.pro industry
PRIMARYHLAHADAF
Surgical Robotics & Computer-Assisted Surgery Platforms
Healthcare & Life Sciences/Medical Devices & Diagnostics/Surgical Instruments, Endoscopy & OR Equipment
SECONDARYHLAHADAB
Endoscopy Systems & Accessories (Scopes, Cameras, Light Sources, Insufflation)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Surgical Instruments, Endoscopy & OR Equipment
SECONDARYHLAHADAA
Open & Minimally Invasive Surgical Instruments (Handheld, Laparoscopic, MIS)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Surgical Instruments, Endoscopy & OR Equipment
SECONDARYHLAKAEAC
Advanced Endoscopy (ERCP/EUS/Interventional)
SECONDARYHDAAAIAC
Healthcare & Assistive Robotics

Keywords

  • Flexible robotic surgery
  • Endoluminal surgical systems
  • Surgical robotics platform
  • Minimally invasive robotics
  • Natural orifice surgery

Where EndoQuest Robotics is headquartered

Location

Headquarters

HQ city
Houston
HQ country
United States
HQ region
North America

Offices2 records

Markets served

EndoQuest Robotics business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Operations, Marketing or Sales, Others

Revenue model

  1. Endoluminal Surgical System (Hardware + Software): Pre-revenue company. The Endoluminal Surgical System is currently in development and not yet FDA cleared or for commercial sale in the U.S. Revenue will be generated through hardware sales of the robotic surgical system along with associated software, instruments, and consumables to healthcare institutions.
  2. Service and Support: Expected to include installation, training, maintenance contracts, and technical support services for healthcare institution customers, typical for medical device capital equipment.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels5 records

EndoQuest Robotics product offering

Product offering

Core offering

EndoQuest Robotics develops the Endoluminal Surgical (ELS) System, a flexible robotic platform that enables minimally invasive surgery through the body's natural orifices (transoral, transanal, transvaginal) or single-incision (transumbilical) approaches. The integrated system comprises a mobile Patient Cart with the EndoDrive flexible steerable delivery system, 6mm flexible robotic instruments with up to 7 degrees of freedom, a 3.7mm HD robotic camera, and an ergonomic Physician Console with heads-up HD monitor and hand/foot controllers. The product is pre-commercial, currently in U.S. FDA IDE pivotal trials.

Product overview

EndoQuest Robotics offers the Flexible Robotic Surgical System as its core product, a comprehensive platform designed to enable endoluminal and single-incision minimally invasive surgery through natural body orifices or minimal incisions. The system consists of three integrated components: the Patient Cart (featuring the EndoDrive and Removable Touchpad), the Flexible Instruments (with up to 7 degrees of freedom), and the Physician Console (with heads-up HD display and hand controllers). The platform is undergoing clinical development with the PARADIGM pivotal trial and is enhanced with AI-powered capabilities through NVIDIA IGX Thor integration for real-time image processing, tissue differentiation, and cloud intelligence. The company maintains worldwide headquarters in Houston, Texas and a South Korea office. The ELS System is under development and has not been FDA cleared for commercial sale in the United States.

Differentiator

Problem solved

Functional benefit

Products and services

  • Endoluminal Surgical (ELS) System A comprehensive flexible robotic surgical platform enabling endoluminal and single-incision procedures through the body's natural orifices (mouth, anus) or transumbilical incision. The integrated system includes a mobile Patient Cart with EndoDrive steerable delivery system, 6mm flexible instruments with up to 7 degrees of freedom, a 3.7mm HD robotic camera, and an ergonomic Physician Console. Designed for hospitals, ambulatory surgical centers, and gastroenterology/colorectal surgeons performing minimally invasive GI and general surgical procedures.

Quantifiable outcome

  • First fully robotic endoscopic submucosal dissection (ESD) procedure by a gastroenterologist successfully removed a 4 cm colorectal lesion

Companies that use EndoQuest Robotics

Customer profile

Named customers2 records

Segments3 records

Ideal customer profiles1 record

EndoQuest Robotics technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Integration2 records

AI capability5 records

Feature6 records

EndoQuest Robotics partnerships and signals

Strategic signal

Partnerships

Five partnerships are on record, tiered core and minor.

  • NVIDIAcoreTechnology or Integration · 18 January 2026EndoQuest expanded collaboration with NVIDIA to integrate AI-powered capabilities into its surgical robotic system. Leveraging NVIDIA's IGX Thor platform for real-time image processing, robotic control, cloud-enabled intelligence, intraoperative tissue differentiation, autonomous surgical tasks, and remote robotic operation capabilities.
  • OMNIVISIONcoreTechnology or Integration · 5 January 2024Partnership to equip the flexible robotic system with industry-leading image sensor technology for enhanced visualization during surgical procedures.
  • ProximieminorStrategic or Co-development Partner · 16 March 2023Multi-year partnership for surgical collaboration and documentation technology integration.
  • VirtaMedminorStrategic or Co-development Partner · 1 February 2023Partnership to develop an endoluminal robotic training simulator for physician education and skill development.
  • Brigham and Women's HospitalcoreStrategic or Co-development Partner · 31 August 2022Installation of the first Endoluminal Surgical System at Brigham and Women's Hospital in Boston, Massachusetts to advance clinical and procedural development of the ELS System.

Scale indicators6 records

Recent moves7 records

Expansion highlights6 records

EndoQuest Robotics competitors and assessment

Company assessment

Direct peers

  • Moon Surgical: Moon Surgical builds a smaller, flexible robotic surgical assistance platform for laparoscopic procedures, aiming to broaden access to robotic surgery. Comparable in stage and ambition to EndoQuest: a smaller, well-funded surgical robotics entrant focused on novel flexible architectures.
  • Asensus Surgical: Asensus Surgical develops the Senhance digital laparoscopic platform and is building a next-gen surgical robotics system with AI-enabled clinical intelligence. Both companies are pursuing digitally enhanced, next-generation minimally invasive surgical systems targeting GI and general surgery.
  • Vicarious Surgical: Vicarious Surgical develops single-incision surgical robotics with decoupled actuators for abdominal procedures. Both companies target minimally invasive surgery through small or single incisions using novel robotic architectures, with EndoQuest focused on flexible endoluminal and Vicarious on transabdominal single-port.

Broad incumbents

  • Boston Scientific: Boston Scientific has significant GI/endoscopy franchises (including single-use endoscopes and ESD tools) and broader minimally invasive surgery businesses. It is a relevant incumbent and potential acquirer/competitor in the GI endoluminal procedure space.
  • Medtronic: Medtronic launched the Hugo robotic-assisted surgery system and has extensive GI/endoscopy businesses (including PillCam and GI solutions). As a broad incumbent, Medtronic competes in both EndoQuest's robotics and downstream GI endoscopy/endoluminal adjacencies.
  • Intuitive Surgical: Intuitive Surgical is the dominant surgical robotics company with the da Vinci platform (including the da Vinci SP single-port system). It operates broadly across urology, gynecology, general surgery, and thoracic, with the largest installed base globally and an unmatched clinical evidence library — a clear incumbent benchmark EndoQuest must compete against.
  • Stryker: Stryker offers the Mako robotic system for orthopedic surgery and acquired MAKO Surgical and Wright Medical, expanding its surgical robotics presence. While primarily orthopedic-focused, Stryker is a broad surgical robotics incumbent with growing interest in minimally invasive and AI-enabled surgery.
  • Olympus Corporation: Olympus is the global leader in GI endoscopy systems and a natural incumbent in flexible endoluminal procedures. While primarily an endoscopy device manufacturer, Olympus has invested in robotic-assisted endoscopy and could expand into endoluminal robotics — directly adjacent to EndoQuest's primary use cases (ESD, myotomy, GI interventions).
  • Johnson & Johnson (Ottava / Verb Surgical): Johnson & Johnson is developing the Ottava general surgery robotic platform and acquired Auris Health for Monarch bronchoscopy/endoluminal robotics. As a broad incumbent with substantial R&D resources, J&J represents the most credible threat to extending into flexible endoluminal surgery.

Emerging players

  • Medrobotics: Medrobotics developed the Flex Robotic System, a flexible robotic platform for natural orifice procedures (transoral, transanal) — directly comparable endoluminal technology. Although the company has faced restructuring, its technical approach and clinical use cases overlap materially with EndoQuest's platform.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks7 records

Key highlights7 records

Customer concentration

EndoQuest Robotics social profiles

Digital presence

EndoQuest Robotics compliance and trust

Trust signal

Compliance1 record

EndoQuest Robotics financial estimates

Financial estimate

Revenue estimate

Valuation estimate

EndoQuest Robotics leadership team

Management profile

Number of profiles

Profiles6 records

EndoQuest Robotics funding detail

Funding detail

Funding overview

Funding rounds5 records

Investors5 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

EndoQuest Robotics M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about EndoQuest Robotics

What does EndoQuest Robotics do?

EndoQuest Robotics develops the Endoluminal Surgical (ELS) System, a flexible robotic platform that enables minimally invasive surgery through the body's natural orifices (transoral, transanal, transvaginal) or single-incision (transumbilical) approaches. The integrated system comprises a mobile Patient Cart with the EndoDrive flexible steerable delivery system, 6mm flexible robotic instruments with up to 7 degrees of freedom, a 3.7mm HD robotic camera, and an ergonomic Physician Console with heads-up HD monitor and hand/foot controllers. The product is pre-commercial, currently in U.S. FDA IDE pivotal trials.

Is EndoQuest Robotics a public or private company?

EndoQuest Robotics is a private company. It is classified as venture growth investor backed and is currently operating.

When was EndoQuest Robotics founded?

EndoQuest Robotics was founded in 2022. It employs 51 to 100 people.

Where is EndoQuest Robotics based?

EndoQuest Robotics is headquartered in Houston, United States, in the North America region.

How does EndoQuest Robotics make money?

Two revenue lines are on record. Endoluminal Surgical System (Hardware + Software) is the primary driver. The others are service and Support.

Who are EndoQuest Robotics's main competitors?

Direct peers on record are Moon Surgical, Asensus Surgical and Vicarious Surgical. Broad incumbents are Boston Scientific, Medtronic, Intuitive Surgical, Stryker, Olympus Corporation and Johnson & Johnson (Ottava / Verb Surgical). Medrobotics is listed as an emerging player.

Does EndoQuest Robotics have an API?

No public API is recorded for EndoQuest Robotics.

What industry is EndoQuest Robotics in?

EndoQuest Robotics's product category is Surgical Robotics. Its primary akta.pro industry code is HLAHADAF, Surgical Robotics & Computer-Assisted Surgery Platforms, with a secondary code of HLAHADAB, Endoscopy Systems & Accessories (Scopes, Cameras, Light Sources, Insufflation). Its NAICS code is 339112 and its SIC code is 3841.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
MedTech DiveEndoQuest Robotics hires chief commercial officerEndoQuest Robotics appointed Jared Eben as chief commercial officer, bringing experience from HCA Healthcare and other medical technology firms. The company is developing a flexible robotic surgery system and aims to launch it in the U.S. next year, with preliminary trial results showing no device-related complications.Medical Device NetworkEnrolment concludes in EndoQuest Robotics’ PARADIGM studyEndoQuest Robotics has concluded subject enrolment in the PARADIGM trial, a multicentre investigational device exemption study evaluating its Endoluminal Surgical system for robotic endoscopic submucosal dissection procedures to remove lesions in the rectum and sigmoid colon. The trial enrolled 49 participants across five US healthcare centres and completed 50 procedures, with preliminary data showing a 100% en bloc resection rate, 100% conversion-free rate, and 95.8% R0 resection rate, with no device-related bleeding or perforations observed. The company plans to include these results in its De Novo Classification Request to the US Food and Drug Administration seeking market authorisation for the ELS system.YahooEnrolment concludes in EndoQuest Robotics’ PARADIGM studyEndoQuest Robotics concluded enrolment in its PARADIGM trial, which involved 49 participants and 50 robotic ESD procedures across five US centres. Preliminary data showed 100% en bloc and conversion-free resection rates, with a 95.8% R0 resection rate and no device-related bleeding or perforations. The company will use these results for its De Novo submission.MassDeviceEndoQuest Robotics completes enrollment in surgical robot trialHouston-based EndoQuest Robotics announced the completion of enrollment in its PARADIGM pivotal FDA investigational device exemption study, concluding 50 robotic endoscopic submucosal dissection procedures across 49 subjects. Preliminary results showed a 100% en bloc resection rate, 100% conversion-free rate, 95.8% R0 resection rate, and no device-related bleeding or perforations. The company plans to include these results in its submission for FDA de novo authorization to bring the ELS surgical robot system to the U.S. market.Business Wire BlogEndoQuest Robotics Announces Completion of Enrollment in the PARADIGM TrialEndoQuest Robotics completed enrollment in its PARADIGM trial after 50 robotic endoscopic submucosal dissection procedures across 49 subjects. Preliminary results show 100% en bloc resection, 100% conversion-free, and 95.8% R0 resection rates, with no device-related bleeding or perforations. The company plans a De Novo submission for the ELS System.openPR.comUnited States Endoscopic Stricture Management Device Market 2026 | Growth Drivers, Trends & Market Forecast, Competitive Landscape & Investment OpportunitiesThe global endoscopic stricture management device market is projected to grow at a compound annual growth rate of 5.6% over the 2024–2031 forecast period, driven by rising prevalence of gastrointestinal, urological, and pulmonary disorders and increasing adoption of minimally invasive procedures. Key recent developments include EndoQuest Robotics receiving FDA approval in January 2026 to begin the final stage of its PARADIGM clinical trial for a robotic-assisted endoscopic system, and Boston Scientific and Olympus both expanding their respective stricture management portfolios in December 2025. Market segmentation analysis indicates gastrointestinal endoscopy holds the largest application share at 40%, while hospitals represent the dominant end-user segment at 55% of the market.MassDeviceEndoQuest gets FDA green light to initiate final stage of surgical robot trialEndoQuest Robotics announced that the FDA approved the initiation of the final stage of its PARADIGM pivotal multicenter trial for the Endoluminal Surgical (ELS) system, a surgical robot designed for lower gastrointestinal tract procedures. The approval follows the submission of safety results for the first cohort of subjects and enables completion of enrollment ahead of a planned de novo classification request in the U.S. The trial is enrolling 50 subjects across five leading U.S. healthcare institutions.Mpo-magEndoQuest Earns FDA Approval for Last Stage of PARADIGM TrialEndoQuest Robotics received FDA approval to complete enrollment for the final stage of its PARADIGM pivotal trial evaluating the Endoluminal Surgical system for endoscopic submucosal dissection procedures. The approval follows submission of safety results from the first set of subjects and advances the company's planned de novo classification request for U.S. market authorization. The trial is enrolling 50 subjects across five leading U.S. healthcare institutions, with the first procedures completed by pioneering gastroenterologists and colorectal surgeons.